Ask AI
ProCE Banner Activity

ASCENT-03: Phase III Trial of 1L Sacituzumab Govitecan vs Chemotherapy for Patients With Advanced TNBC Ineligible for PD-1/PD-L1 Inhibitors

Conference Coverage
Slideset

Primary results from the phase III ASCENT-03 trial showed that the TROP-2–directed antibody–drug conjugate sacituzumab govitecan significantly improved progression-free survival vs chemotherapy for patients with previously untreated metastatic triple-negative breast cancer who were not eligible for PD-1/PD-L1 inhibitors.

Released: October 24, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly